According to the Zhitong Finance APP, Gerui Pharmaceutical-B (01672) rose more than 11%, as of press time, up 11.25%, reported HKD 0.89, with a turnover of HKD 2.3683 million.

According to the news, Gerui Pharmaceutical announced that it plans to repurchase shares on the open market based on market conditions, using up to HKD 200 million in funds for the proposed share repurchase. The Board of Directors believes that the proposed share repurchase reflects the company's confidence in its long-term business prospects and growth potential, and will ultimately benefit the company and its shareholders as a whole.

Northeast Securities previously pointed out that the company focuses on the development of drugs for viral diseases, non-alcoholic fatty liver disease, and tumors and other fields, with considerable potential. The milestone event in 2024 is expected to continue to enhance the company's value, and it is recommended to pay attention to relevant catalysts.